Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNC101 + FOLFIRI
- Development stage
- Unknown
- Lead developer
- Neuphoria Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
BNC101 + FOLFIRI is an investigational combination therapy for cancer. BNC101 is a monoclonal antibody targeting LGR5 (leucine-rich repeat-containing G-protein coupled receptor 5), which is implicated in cancer stem cell biology and tumor growth. FOLFIRI is a well-established chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. In this combination: - BNC101 acts by binding to LGR5 on cancer stem cells, potentially inhibiting their ability to drive tumor growth and recurrence. - The components of the FOLFIRI regimen work as follows: - Folinic acid enhances the effectiveness of fluorouracil. - Fluorouracil inhibits DNA synthesis by acting as an antimetabolite. - Irinotecan inhibits topoisomerase I, preventing DNA replication in rapidly dividing cells. This combination has been studied primarily for metastatic colorectal cancer and may be under investigation for other solid tumors.
- Brand names
- Camptosar
- Other names
- irinotecan de Gramontirinotecan modified de GramontIrMdG
02
Targets
LGR5 (Leucine-rich repeat-containing G-protein coupled receptor 5)TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on BNC101 + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNC101 + FOLFIRI.